Abstract
We investigated the effect of octreotide in the treatment of severe acute pancreatitis in a case–control study. Experimental and clinical studies on the effect of octreotide in the treatment of acute pancreatitis have shown controversial results. Since January 1992, we have been conducting a prospective randomized study on the effect of octreotide in severe acute pancreatitis, in three hospitals in Israel. The entering criteria included three or more of the Ranson prognostic signs and CT findings of severe pancreatitis. Patients were randomly assigned to conservative treatment either with or without octreotide (0.1 mg subcutaneously three times a day). The end points of the study included: complication rate (ARDS, sepsis, renal failure, pseudocyst, fistula, and abscess), length of hospital stay, and mortality. From January 1992 to December 1996, 60 patients entered the study. After evaluating the files, 10 patients were excluded due to failure to meet the entering criteria, incomplete data, or incorrect diagnosis. Of the remaining 50 patients, 25 were assigned to octreotide (treatment group) and 25 to conservative treatment only (control group). The two groups matched with regard to age, sex, etiology, and severity of the disease. The complication rate was lower in the treatment group with regard to sepsis (24% vs 76%, P = 0.0002) and ARDS (28% vs 56%, P = 0.04). The hospital stay was shorter in the treatment group (20.6 vs 33.1 days, P = 0.04). Two patients died in the treatment group and eight in the control group (P < 0.019). These results suggest that octreotide may have a beneficial effect in the treatment of severe acute pancreatitis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
REFERENCES
Becker V: Pathological anatomy and pathogenesis of acute pancreatitis. World J Surg 5:303–313, 1981
Ranson JHC, Rifkind KM, Roses DF, Fink SD, Eng K, Spencer FC: Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet 139:69–81, 1974
Ranson JHC, Balthazar E, Caccavali R, Cooper M: Computed tomography and the prediction of pancreatic abscess in acute pancreatitis. Ann Surg 201:656–663, 1985
Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179:77–79, 1973
Polak J, Pearse AGE, Grimelius L, Bloom S, Arimura A: Growth-hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells. Lancet 1:1220–1222, 1975
Reichlin S: Somatostatin. N Engl J Med 309:1556–1563, 1983
O'Donnell LJD, Farthing MJG: Therapeutic potential of a long acting somatostatin analogue in gastrointestinal diseases. Gut 30:1165–1172, 1989
Hurst RD, Modlin IM: The therapeutic role of octreotide in the management of surgical disorders. Am J Surg 162:499–507, 1991
Williams ST, Woltering EA, O'Dorisio TM, Fletcher WS: Effect of octreotide acetate on pancreatic exocrine function. Am J Surg 157:459–462, 1989
Paran H, Neufeld D, Mayo A, Shwartz I, Singer P, Kaplan O, Skornik Y, Klausner J, Freund U: Preliminary report of a prospective randomized study of octreotide in the treatment of severe acute pancreatitis. J Am Coll Surg 181:121–124, 1995
Buchler M, Malfertheiner P, Friess H, Isenmann R, Vanek E, Grimm H, Schlegel P, Friess T, Beger HG: Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology 103:1902–1908, 1992
Isenmann R, Buchler M, Friess H, Uhl H, Beger HG: Antibiotics in acute pancreatitis. Dis Surg 13:365–369, 1996
Lamberts SWJ, Van der Lely AJ, de Herder WW, Hofland LJ: Octreotide. N Engl J Med 334:246–254, 1996
Lankish PG, Koop H, Winckler K, Folsch UR, Creutzfeldt W: Somatostatin therapy of acute experimental pancreatitis. Gut 18:713–716, 1977
Schwedes U, Althoff PH, Klempa I, Lenshner U, Mothes L, Raptis S, Wdowinski J, Usadel Kh: Effect of somatostatin on bile-induced acute hemorrhagic pancreatitis in the dog. Horm Metab Res 11:655–661, 1979
Baxter JN, Jenkins SA, Day DW, Roberts NB, Cowell DC, Mackie CR, Shields R: Effect of somatostatin and long-acting somatostatin analogue on the prevention and treatment of experimentally induced acute pancreatitis in the rat. Br J Surg 72:382–385, 1985
Degertekin H, Ertan A, Akdamar K, Yates R, Chen I, Coy H, Arimura A: Effects of somatostatin and a somatostatin agonist on diet-induced pancreatitis in mice. Peptides 6:1245–1247, 1985
Murayama KM, Drew FB, Joehl RJ: Does somatostatin analogue prevent experimental acute pancreatitis? Arch Surg 125:1570–1572, 1990
Metrakos P, Rosenberg L, Duguid WP, Fried GM: Prophylactic sandostatin potentiates acute pancreatitis. Surg Forum 41:160–161, 1990
Tulassay Z, Nemeth J, Vargas G, Papp M: Effect of somatostatin on experimental pancreatic lesions and their sequelae. Orv-Hetil 132:1631–1638, 1991
Steinberg W, Tenner S: Acute pancreatitis. N Engl J Med 330:1198–1210, 1994
Usadel Kh, Uberria KK, Leuschner U: Treatment of acute pancreatitis with somatostatin: Results of the multicenter double-blind trial (APTS-study). Dig Dis Sci 30:992, 1985 (abstract)
Choi TK, Mok F, Zhan WH, Fan ST, Lai EC, Wong J: Somatostatin in the treatment of acute pancreatitis: A prospective randomized controlled trial. Gut 30:223–227, 1989
Beechey-Newman N: Controlled trial of high-dose octreotide in treatment of acute pancreatitis. Evidence of improvement in disease severity. Dig Dis Sci 38:644–647, 1993
Sanchez AR, Sanchez DF, Chimp'n VR: Acute pancreatitis: Clinical and therapeutic study with somatostatin. Rev Clin Esp 197:96–99, 1997
McKay C, Baxter J, Imrie C: A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis. Int J Pancreatol 21:13–19, 1997
Paran H, Klausner J, Siegal A, Graff E, Freund U, Kaplan O: Effect of the somatostatin analogue octreotide on experimental pancreatitis in rats. J Surg Res 62:201–206, 1996
Reichlin S: Neuroendocrine-immune interactions. N Engl J Med 329:1246–1253, 1993
Fais S, Annibale B, Boirivant M, Santoro A, Pallone F, Delle-Fave G: Effects of somatostatin on human intestinal lamina propria lymphocytes. J Neuroimmunol 31:211–219, 1991
Payan DG, Goetzl EJ: Modulation of lymphocytes function by sensory neuropeptides. J Immunol 135:783–786, 1985
VanHagen PM, Krenning EP, Kweekkeboom DJ, Reubi JC, Anker-Lugtenburg PJ, Lowenberg B, Lamberts SW: Somatostatin and the imune and haematopoetic system: A review. Eur J Clin Invest 24(2):91–99, 1994
Nio DA, Moylan RN, Roche JK: Modulation of T lymphocyte function by neuropeptides. Evidence for their role as immunoregulatory elements. J Immunol 150(12):5281–5288, 1993
Fais S, Annibale B, Boirivant M, Santoro A, Pallone F, Delle-Fave G: Effects of somatostatin on human intestinal lamina propria lymphocytes. J Neuroimmunol 31(3):211–219, 1991
Kolasisnsky LS, Haines KA, Siegel EL, Cronstein BN, Abramson SB: Neuropeptides and inflamation: A somatostatin analogue as a selective antagonist on neutrophil activation by substance P. Arthritis Rheum 35:369–375, 1992
Karalis K, Mastorakos G, Chrousos GP, Tolis G: Somatostatin analogs supress the inflammatory reaction in vivo. J Clin Invest 93:2000–2006, 1994
Fiedler F, Jauernig G, Keim V, Richter A, Bender HJ: Octreotide treatment in patients with necrotizing pancreatitis and pulmonary failure. Intensive Care Med 22(9):909–915, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Paran, H., Mayo, A., Paran, D. et al. Octreotide Treatment in Patients with Severe Acute Pancreatitis. Dig Dis Sci 45, 2247–2251 (2000). https://doi.org/10.1023/A:1026679106463
Issue Date:
DOI: https://doi.org/10.1023/A:1026679106463